Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Announces New License Agreement


Friday, 11 Oct 2013 06:30am EDT 

ImmunoGen, Inc announced that Novartis has licensed the right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target. This is the second license to be taken by Novartis under a 2010 agreement between the companies. 

Company Quote

11.52
0.03 +0.26%
22 Aug 2014